Drugs / Entecavell ODT
Entecavell ODT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07267208 | Dec 2025 → Dec 2027 expected | hepatitis B virus infection | Jongman Kim | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Entecavell ODT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07267208 ↗ |
| Known as | Entecabell ODT | “After conversion, participants will take Entecabell ODT 0.5 mg once daily for 48 weeks and will be followed according to the scheduled visits and assessments.” NCT07267208 ↗ |
| Known as | Entecavir ODT | “Entecavir ODT is administered once every day with 0.5mg PO for 48 weeks.” NCT07267208 ↗ |
| Route | Oral | “Entecavir ODT is administered once every day with 0.5mg PO for 48 weeks.” NCT07267208 ↗ |